94% of patients suing Merck over rofecoxib agree to company’s offerBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39513.541296.DB (Published 13 March 2008) Cite this as: BMJ 2008;336:580
- Fred Charatan
A large enough proportion of the litigants suing Merck after taking the drug rofecoxib (Vioxx) have agreed to the terms of the company’s offer to allow the settlement to go ahead.
Eighty five per cent of claimants had to agree to the settlement to proceed, and by the beginning of this month 94% (44 000 of the 47 000) had done so. The company announced in November a settlement worth $4.85bn (£2.41bn; €3.15bn).
The individual awards, estimated at $150 000 to $200 000 on average, will be …